Key result
Bivalirudin reduced the incidence of major bleeding by 34% compared to heparin in patients undergoing percutaneous coronary intervention, though additional use of GP IIb/IIIa inhibitors weakened this benefit.
Why the study?
Does bivalirudin with or without GP IIb/IIIa inhibitors reduce ischemic or bleeding events compared to heparin in patients undergoing PCI?
Meta-Analysis (n=38,096)
Does bivalirudin with or without GP IIb/IIIa inhibitors reduce ischemic or bleeding events compared to heparin in patients undergoing PCI?
Bivalirudin reduces major bleeding compared to heparin during PCI, though concurrent use of GP IIb/IIIa inhibitors attenuates this safety benefit.
Answers are grounded in this paper and cite their sources.
Favors bivalirudin to reduce bleeding in PCI; confirms meta-analyses while underscoring GP IIb/IIIa attenuation.
The safety and effectiveness of using the direct thrombin inhibitor bivalirudin during transcatheter coronary interventional procedures remains uncertain.This study aimed to systematically assess anticoagulation with bivalirudin alone or bivalirudin plus glycoprotein (GP) IIb/IIIa inhibitors (bivalirudin-based anticoagulant therapy) in patients undergoing percutaneous coronary intervention (PCI) procedures by a meta-analysis of randomized controlled trials (RCTs).Systematical searches of the MEDLINE, EMBASE, and Cochrane databases were conducted. RCTs comparing bivalirudin-based anticoagulant therapy with a comparable heparin therapy in patients undergoing PCI were eligible. Risk ratios (RRs) with 95% confidence intervals (CIs) served as summary statistics.A total of 38,096 patients from 17 RCTs were randomized to the bivalirudin group (n = 18,878) or heparin group (n = 19,218) in the meta-analysis. No significant differences in death, myocardial infarction or reinfarction, ischemia-driven revascularization, or in-stent thrombosis were observed between the 2 groups (all P > 0.05). Notably, bivalirudin-based therapy showed a highly significant 34% decrease in the incidence of major bleeding (RR = 0.66; 95% CI 0.54-0.81; P < 0.001) and a 28% reduction in the need for blood transfusion (RR = 0.72; 95% CI 0.56-0.91; P < 0.01). Meta-regression analyses demonstrated that additional administration of GP IIb/IIIa receptor inhibitors (P = 0.01), especially eptifibatide (P = 0.001) and tirofiban (P = 0.002), was likely to increase the major bleeding risk associated with bivalirudin.Bivalirudin, in comparison to heparin, is associated with a markedly lower risk of major bleeding, and the additional use of GP IIb/IIIa inhibitors may weaken this benefit.
No takes yet. Share an insight, caveat, or question.
Li et al. (2015) conducted a meta-analysis in Patients undergoing percutaneous coronary intervention (PCI) (n=38,096). Bivalirudin alone or bivalirudin plus glycoprotein (GP) IIb/IIIa inhibitors vs. Heparin (unfractionated or low-molecular-weight) plus planned or provisional GP IIb/IIIa inhibitors was evaluated on Major bleeding (RR 0.66, 95% CI 0.54-0.81, p=<0.001). Bivalirudin reduced the incidence of major bleeding by 34% compared to heparin in patients undergoing percutaneous coronary intervention, though additional use of GP IIb/IIIa inhibitors weakened this benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: